KAPL readies to meet demand for oxytocin as September 1 deadline nears

KAPL plan to create a buffer stock of 5 million ampules, by August 31

KAPL readies to meet demand for oxytocin as September 1 deadline nears
<a href="http://www.shutterstock.com/pic-228848833/stock-photo-pills-drug.html" target="_blank">Image</a> via Shutterstock
Sohini Das Mumbai
Last Updated : Jul 28 2018 | 10:47 PM IST
As the Centre is all set to restrict the manufacture and sale of oxytocin from September 1, a crucial hormone used to control labour and postpartum bleeding in pregnant women, public sector firm Karnataka Antibiotics Pvt Ltd (KAPL) is gearing up to meet demand from all across the country in a month.

Apart from ramping up production, the dual challenge is to make the hormone reach the end user in remote corners of the country, at a time when the government is planning to forbid sale of oxytocin (in any name or form) through the retail chemist. Import is also forbidden. KAPL managing director Nirja Saraf told Business Standard that they already have a stock of 1.8 million ampules of oxytocin with them, and they plan to create a buffer stock of 5 million ampules, by August 31. Saraf added that the monthly requirement for the hormone is around 2.5 million ampules.

KAPL will have a two-month stock when the restriction comes into effect on September 1. The Bengaluru-based firm has a capacity of 5.5 million units of ampules per month using one production line. It is now using almost 70 per cent of the capacity. 

Saraf informed that it is now converting an existing unit into an ampule manufacturing one. Once this is completed by December, the total capacity for ampules would be around 8 million per month. KAPL is investing around Rs 30 million into this capacity expansion drive.

It has also started planning to ensure the drug reaches the remote corners — around 19 clearing and forwarding (C&F) agents would cover 29 states, seven Union Territories and 712 districts, said Saraf. "We are also appointing our existing distributors (around 160 of them) to take care of the interior districts," she added.

While KAPL is gearing up to ensure there is no supply disruption, there is some apprehension in the market about shortages of this crucial drug.

US-headquartered drug maker Mylan, for example, has moved the Delhi High Court challenging the government notification.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story